What is the duration of nausea/vomiting with zolbetuximab?

Published

There is no full analysis examining duration of nausea/vomiting in Phase 3 trials; limited post hoc data show median nausea duration 3 days and vomiting 1 day

A post hoc integrated analysis of Phase 2 (FAST, ILUSTRO) and Phase 3 (SPOTLIGHT, GLOW) studies was conducted comparing zolbetuximab + EOX/mFOLFOX6/CAPOX (n = 631) with EOX or placebo + mFOLFOX6/CAPOX (n = 611).1

Caution should be used in interpreting the results of this post-hoc analysis due to limitations in data collection.1 If nausea or vomiting changed grade, there was no adverse event identification to link it and the duration included in the analysis was not the full duration of the event.

Table 1. Duration of nausea/vomiting events in the integrated FAST/ILUSTRO/SPOTLIGHT/GLOW studies (safety analysis set)1

aIncluding patients who received zolbetuximab 800/600 mg/m2 + EOX (FAST), mFOLFOX6 (ILUSTRO or SPOTLIGHT) or CAPOX (GLOW).

bIncluding patients who received EOX alone (FAST), Placebo + mFOLFOX6 (SPOTLIGHT) or CAPOX (GLOW).

Abbreviations: CAPOX: capecitabine and oxaliplatin; EOX: epirubicin, oxaliplatin, capecitabine; max: maximum; min: minimum; mFOLFOX6: modified 5-fluorouracil, leucovorin (or folinic acid) and oxaliplatin; PBO: placebo.

  1. Data on File.

find-my-msl

Find My MSL

Medical Science Liaisons are available to help answer your scientific questions.

submit

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

adverse

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)